The 2010 update of the ESC guidelines for the management of atrial fibrillation - Beyond the rate or rhythm strategy debate

Circulation Journal

Volumn 74, Issue 12, 2010, Pages 2538-2541

  Fung, Jeffrey W H ^a   Yu, Cheuk Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRONEDARONE; FLECAINIDE; PROPAFENONE; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING TENDENCY; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG EFFICACY; DRUG SAFETY; EUROPEAN UNION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION TEST; HUMAN; HYPERTENSION; PATIENT CARE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; RISK FACTOR; SINUS RHYTHM; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ATRIAL FIBRILLATION; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 78649695931     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1042     Document Type: Article

References (43)

1. Go AS, Hylek EM, Philips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrilla tion of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
3. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046.
4. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention. Circulation 2003; 108: 711-716.
5. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of Mainland China. J Epidemiol 2008; 18: 209-216.
6. Ohsawa M, Kotani M, Tajima Y, Tsuji D, Ishibashi Y, Kuroki A, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol 2005; 15: 194-196.
7. KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: A population-based study. J Electrocardiol 2008; 41: 94-98.
8. Jeong HJ. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005; 20: 26-30.
9. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
10. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, et al, GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001; 86: 527-532.
11. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
12. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
13. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
14. Smith SC Jr, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, et al. Principles for national and regional guidelines on cardiovascular disease prevention. Circulation 2004; 109: 3112-3121.
15. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
16. Van Gelder IC, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
17. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al, STAF Investigators. Randomized trial of rate-control versus rhythmcontrol in persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690-1696.
18. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-486.
19. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
20. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
21. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000; 356: 1789-1794.
22. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
23. Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, et al. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21: 946-958.
24. Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: Epidemiology, acute care, and postacute outcomes. Stroke 2005; 36: 374-386.
25. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke 2002; 33: 230-236.
26. Ayala C, Greenlund KJ, Croft JB, Keenan NL, Donehoo RS, Giles WH, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol 2001; 154: 1057-1063.
27. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke 2008; 39: 2736-2743.
28. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation: A nationwide descriptive study in Taiwan. Clin Ther 2008; 30: 1726-1736.
29. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
30. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al, for the ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
31. Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp- Pedersen C, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation: Insights from the ATHENA trial. Abstract 4097. In: Proceedings of the American Heart Association Scientific Sessions, November 2008, New Orleans, USA.
32. Køber L, Torp-Pedersen C, McMurray JJV, Gøtzsche O, Lévy S, Crijns H, et al, for the Dronedarone Study Group. Increased mortality after dronedarone for severe heart failure. N Engl J Med 2008; 358: 2678-2687.
33. Le Heuzey JY, De Ferrari GM, Radzick D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597-605.
34. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
35. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20- year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
36. Hansson A, Madsen-Hardig B, Olsson SB. Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: A study based on interviews with 100 patients seeking hospital assistance. BMC Cardiovasc Disord 2004; 4: 13.
37. Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20: 138-144.
38. Cappato R, Calkins H, Chen SA, Davies W, Lesaka Y, Kalman J, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53: 1798-1803.
39. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. Circulation 2009; 119: 606-618.
40. Cosio FG, Aliot E, Botto GL, Heidbüchel H, Geller CJ, Kirchhof P, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: Reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008; 10: 21-27.
41. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, et al; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614-1619.
42. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al; MADIT II Investigators. Inappropriate implantable cardioverter- defibrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-1365.
43. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick D, et al. Search AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction (SAVE PACe) Trial: Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007; 357: 1000-1008